PubMed for id: 81037

Year	Number of Results
2001	1
2002	1
2003	1
2004	1
2008	2
2009	6
2010	12
2011	13
2012	10
2013	16
2014	24
2015	13
2016	7
2017	5
2018	4
2019	11
2020	11
2021	9
2022	11
2023	5
2024	0

1

Exploring the Relationship between CLPTM1L-MS2 Variants and Susceptibility to Bladder Cancer.

Jeong MS, Mun JY, Yang GE, Kim MH, Lee SY, Choi YH, Kim HS, Nam JK, Kim TN, Leem SH. Jeong MS, et al. Genes (Basel). 2023 Dec 28;15(1):50. doi: 10.3390/genes15010050. Genes (Basel). 2023. PMID: 38254939 Free PMC article.

2

CLPTM1L is a GPI-anchoring pathway component targeted by HCMV.

Kol I, Rishiq A, Cohen M, Kahlon S, Pick O, Dassa L, Stein N, Bar-On Y, Wolf DG, Seidel E, Mandelboim O. Kol I, et al. J Cell Biol. 2023 Sep 4;222(9):e202207104. doi: 10.1083/jcb.202207104. Epub 2023 Jun 30. J Cell Biol. 2023. PMID: 37389656 Free PMC article.

3

Genome-wide CRISPR screen reveals CLPTM1L as a lipid scramblase required for efficient glycosylphosphatidylinositol biosynthesis.

Wang Y, Menon AK, Maki Y, Liu YS, Iwasaki Y, Fujita M, Guerrero PA, Silva DV, Seeberger PH, Murakami Y, Kinoshita T. Wang Y, et al. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2115083119. doi: 10.1073/pnas.2115083119. Epub 2022 Mar 28. Proc Natl Acad Sci U S A. 2022. PMID: 35344438 Free PMC article.

4

CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells.

Li H, Che J, Jiang M, Cui M, Feng G, Dong J, Zhang S, Lu L, Liu W, Fan S. Li H, et al. Cell Commun Signal. 2020 Sep 17;18(1):152. doi: 10.1186/s12964-020-00571-4. Cell Commun Signal. 2020. PMID: 32943060 Free PMC article.

5

Prognostic significance of CLPTM1L expression and its effects on migration and invasion of human lung cancer cells.

Ni Z, Chen Q, Lai Y, Wang Z, Sun L, Luo X, Wang X. Ni Z, et al. Cancer Biomark. 2016;16(3):445-52. doi: 10.3233/CBM-160583. Cancer Biomark. 2016. PMID: 27062701

6

CLPTM1L polymorphism and lung cancer risk.

Tang M, Bian X, Zhao Q. Tang M, et al. Int J Clin Exp Med. 2015 Mar 15;8(3):3895-900. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26064290 Free PMC article.

7

Association between CLPTM1L-TERT rs401681 polymorphism and risk of pancreatic cancer: a meta-analysis.

Liu CL, Zang XX, Wang C, Kong YL, Zhang H, Zhang HY. Liu CL, et al. Clin Exp Med. 2015 Nov;15(4):477-82. doi: 10.1007/s10238-014-0316-3. Epub 2014 Oct 5. Clin Exp Med. 2015. PMID: 25284078

8

Correlation of CLPTM1L polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population.

Liang Y, Thakur A, Gao L, Wang T, Zhang S, Ren H, Meng J, Geng T, Jin T, Chen M. Liang Y, et al. Tumour Biol. 2014 Dec;35(12):12075-82. doi: 10.1007/s13277-014-2508-6. Epub 2014 Aug 26. Tumour Biol. 2014. PMID: 25155038

9

CRR9p polymorphism as a protective factor for lung cancer.

Chen Y, Yu Z, Zhang B, Chang Z, Wang H, Liu Z. Chen Y, et al. Tumour Biol. 2014 Oct;35(10):9557-62. doi: 10.1007/s13277-014-2198-0. Epub 2014 Jun 24. Tumour Biol. 2014. PMID: 24957041

10

Association between CLPTM1L polymorphisms (rs402710 and rs401681) and lung cancer susceptibility: evidence from 27 case-control studies.

Zhao DP, Yang CL, Zhou X, Ding JA, Jiang GN. Zhao DP, et al. Mol Genet Genomics. 2014 Oct;289(5):1001-12. doi: 10.1007/s00438-014-0868-7. Epub 2014 Jun 7. Mol Genet Genomics. 2014. PMID: 24907075

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

144 results

Results by year